Introduction {#s1}
============

Essential tremor (ET) is often reported to be among the most prevalent movement disorders, and it is the most common cause of abnormal tremor in humans.[@b01] The incidence of ET rises with age.[@b02],[@b03] Furthermore, the reported increased risk of mortality associated with ET is modest,[@b04] and, therefore, incident cases accumulate with time, contributing to the often-observed age-associated rise in disease prevalence.[@b01],[@b05],[@b06]

Despite its reportedly high prevalence, the precise number of ET cases in the USA is not known. One often-cited paper, published in 1995, estimated that 13.5 million Americans had ET,[@b07] and given the growth in the US population over the past 19 years, one would expect that an even larger number of Americans now have ET. However, the methods used to derive the estimate of 13.5 million are not completely transparent.[@b07] Websites for disease-specific organizations, such as the International Essential Tremor Foundation, report that there are an estimated 10 million Americans with ET. Again, the basis for this estimate is not clear.

Knowing the number of ET cases is important for estimating the medical burden on communities and society, and providing an objective metric on which to base health resource planning. The goal of the current analyses was to use published data from epidemiological studies to derive an estimate of the number of people currently residing in the USA who have ET.

Methods {#s2}
=======

A PubMed search was conducted in May 2014 in order to identify published population-based prevalence studies of ET. The search terms were "prevalence", "incidence", "epidemiology", "population", and "essential tremor", and all full-length English language papers were identified. One full-length paper in Chinese was excluded.[@b08] The search yielded 34 population-based prevalence studies.[@b01],[@b09]--[@b14] The methodology of each identified study was assessed, and methodologically more rigorous studies were selected for further review. The methodological issues of greatest importance were as follows: 1) all subjects in the sample received an in-person neurological examination or the study provided information to indicate that the sensitivity of the screening questionnaire used during the first phase of case ascertainment was high, 2) neurologists assigned the ET diagnoses, 3) the study used diagnostic criteria that sufficiently separate ET from other entities such as enhanced physiological tremor, which are common in the population, and 4) the study provided separate age-specific estimates of prevalence. Age-specific prevalence data from the selected studies were then abstracted. US census data from 2012 were used to derive counts of the population in the USA by 10-year age categories.[@b15]

Results {#s3}
=======

The search identified 34 population-based prevalence studies, including 28 reviewed by Louis et al. in 2010 and six published after that point.[@b01],[@b09]--[@b14] Of these 34 studies, 16 were identified in which: 1) the method of case ascertainment involved either neurological examination of all subjects in a population sample or administration of a screening questionnaire followed by neurological examination, and the sensitivity of the screen was provided, and 2) estimates of prevalence were provided within age strata.[@b05],[@b06],[@b11],[@b12],[@b14],[@b16]--[@b26] Of these 16,[@b05],[@b06],[@b11],[@b12],[@b14],[@b16]--[@b26] 12 used diagnostic criteria for ET that are not ideally suited to epidemiological investigations (e.g., the Consensus Statement of the Movement Disorder Society[@b27]) because they do not sufficiently separate ET from other entities such as enhanced physiological tremor, and/or used non-neurologists to assign ET diagnoses, which is not optimal. Four studies remained; these were conducted in Israel,[@b18] Turkey,[@b05],[@b20] and Spain.[@b14] The age-specific prevalence of ET is displayed for each of these four studies ([Table 1](#t01){ref-type="table"}).[@b05],[@b14],[@b18],[@b20] One of these studies[@b18] focused exclusively on a specific ethnic group (Arab villagers in Northern Israel) and the prevalence estimates were one order of magnitude lower than those reported in the other three studies;[@b05],[@b14],[@b20] hence it was excluded, leaving three remaining studies.[@b05],[@b14],[@b20]

Table 1Prevalence Data for ET (per 100) by Age Category in Four Selected StudiesAge Category (Years)[^1^](#TFN02t01){ref-type="table-fn"}Dogu et al.[@b05] (Turkey)Glick et al.[@b18] (Israel)Sur et al.[@b20] (Turkey)Seijo-Martinez et al.[@b14] (Spain)18--300.7931--400.8340--492.81.56[^2^](#TFN03t01){ref-type="table-fn"}50--593.52.89[^2^](#TFN03t01){ref-type="table-fn"}60--695.93.88[^2^](#TFN03t01){ref-type="table-fn"}65--690.5765--747.3570--796.50.7275--849.9271 and older9.3480 and older8.71.4785 and older11.24[^1][^2][^3]

Prevalence data from each of the three remaining studies were used, in conjunction with 2012 US Census data, to estimate the number of individuals in the USA with ET in 2012. First, using data from the study in Istanbul, Turkey,[@b20] one would estimate that 6.38--6.78 million individuals in the USA have ET. This estimate used age-specific ET prevalence data from Istanbul for ages 18 and older. For individuals who were younger than age 18, we used incidence data for ET from Rochester, Minnesota,[@b03] which indicated that 14 of 266 (5.3%) ET cases arise prior to age 20 years. Using these data, we made two alternative assumptions. The first assumption was that none of the ET cases whose tremor began prior to age 20 was still younger than 20; the second assumption was that all of these ET cases were still younger than 20. The alternative assumptions resulted in two different estimates, 6.38 and 6.78 million for assumptions 1 and 2, respectively. Second, using data from the study in Mersin, Turkey,[@b05] we estimated that 7.23--7.63 million individuals in the USA have ET. To derive this estimate, we used the published age-specific estimates from Mersin for ages 40 or older. To include younger individuals, we used data from the study in Istanbul[@b20] for individuals aged 18--40, and data from Rochester, Minnesota[@b03] for individuals aged 18 and younger. We made the same two alternative assumptions described above about the current ages of childhood onset cases. Third, using data from the study in Spain,[@b14] we estimated that 6.75--7.15 million individuals in the USA have ET. This estimate was based on published age-specific estimates from Spain for individuals aged 65 or older. For younger individuals, we used data from the study in Istanbul[@b20] for those aged 18--65 and data from Rochester, Minnesota[@b03] for those aged 18 or younger. Again, we used the same two alternative assumptions as in the other studies about the current ages of childhood onset cases.

For all three studies, the estimates of the number of individuals with ET in the USA (2012) range from 6.38--7.63 million (mean = 7.01 million).

Discussion {#s4}
==========

In the current study, we estimated that approximately 7 million people in the USA have ET. This represents 2.2% of the US population. By comparison, the number of people with Parkinson\'s disease, another tremor disorder, is estimated at 0.5--1 million, or about 0.15--0.3% of the population.

ET is one of the most common neurological diseases, and with 7 million people in the country affected, it is expected to result in considerable health care expenditures. Its effects on loss of work productivity have not been determined on a broad societal level. One study reported that 25% of ET cases were forced to change jobs or take early retirement because of tremor;[@b28] however, the ET cases were recruited to a specialty care center rather than from the population, so it is difficult to extrapolate these data to cases in the general population, who often have tremor that is milder than that seen in clinic patients.[@b29],[@b30] No studies have attempted to estimate the magnitude of health care expenditures associated with ET, yet this is an issue of great import.

There are a number of important caveats to consider. All of the three selected epidemiological studies had design features that were most likely to have optimally captured ET cases and assigned valid diagnoses; however, they were carried outside of the USA.[@b05],[@b14],[@b20] Despite this, age-specific prevalence estimates across the same age categories in these three studies were largely in agreement with one another, making it likely that they are a reasonable approximation of the true prevalence of ET and a reasonable starting point for approximating the prevalence of ET in the USA. In addition, there is currently no alternative but to use these data. The second issue is that data on the prevalence of ET in children were derived from a single study of the incidence rather than the prevalence of ET. Hence, the estimates we used made two opposing assumptions to provide the reader with both the most and the least conservative estimates. Regardless, the incidence and prevalence of ET are very low in children, and the two diametrically opposed assumptions resulted in estimates that were in the same general range.

In summary, the current study estimates that 7.01 million individuals in the USA have ET. This corresponds to approximately 2.2% of the US population. Knowing the number of ET cases is important for estimating the medical burden on communities and society, and providing an objective metric on which to base health resource planning.
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[^1]: Abbreviation: ET, Essential Tremor.

[^2]: Several studies used different age cut points.

[^3]: Actual age categories were 41--50, 51--60, and 61--70 years.
